Menu
← Oncology Approval Tracker
FDA DECISION ·
Loqtorzi + cisplatin + gemcitabine
toripalimab-tpzi + cisplatin + gemcitabine · Coherus BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, with cisplatin and gemcitabine.
LAMPGEN ANALYSIS
Why it matters
This introduced a PD-1 inhibitor plus chemotherapy in a rare head and neck cancer setting.
What research teams should watch
Confirm nasopharyngeal primary site and distinguish first-line use from the separately approved single-agent use.
PRIMARY RECORDS